Medication approval journey
zolpidem (Ambien)
Approved for Short-term treatment of insomnia
Before changing anything
Stopping abruptly can be dangerous — never do it without medical supervision
Z-drugs act on the same receptor system as benzodiazepines. Stopping abruptly after regular use can cause severe rebound insomnia and, at higher doses, seizures. Any change should be a prescriber-supervised taper.
How long the trials actually ran
The longest trial behind the zolpidem approval ran 5 weeks.
The gap between how long the trials ran and how long people actually take these medications is the single most important thing on this page. It is not evidence that longer use is unsafe or ineffective. It is evidence that longer use was not what got tested.
The boxed warning
The strongest warning the FDA puts on a label, reproduced word for word — not our summary of it.
WARNING: COMPLEX SLEEP BEHAVIORS Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of Zolpidem tartrate extended-release tablets. Some of these events may result in serious injuries, including death. Discontinue Zolpidem tartrate extended-release tablets immediately if a patient experiences a complex sleep behavior [see Contraindications (4) and Warnings and Precautions (5.1) ]. WARNING: COMPLEX SLEEP BEHAVIORS See full prescribing information for complete boxed warning. Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of Zolpidem tartrate extended-release tablets. Some of these events may result in serious injuries, including death. Discontinue Zolpidem tartrate extended-release tablets immediately if a patient experiences a complex sleep behavior. ( 4 , 5.1 )
FDA label effective August 26, 2026 — read the full label on DailyMed
How many Americans take zolpidem
Survey-based federal estimates, published with a lag of about two years. They count prescriptions filled, not outcomes.
- 12,744,221
- prescriptions in the United States (2024)
- 2,420,367
- people filling them (2024)
Prescriptions are down 43% since 2014. Whatever you decide about zolpidem, you are deciding alongside about 2,420,367 other people this year.
Source: ClinCalc DrugStats (Medical Expenditure Panel Survey (MEPS), Agency for Healthcare Research and Quality), CC BY-SA 4.0, release 2026.08.
What people report to the FDA about zolpidem
Read this before the numbers.
Anyone can file an adverse event report — patients, doctors, manufacturers — and nobody verifies that the drug caused what was reported. There is no denominator: tens of millions of prescriptions generate reports at an unknowable rate, and reporting rises with news coverage, not necessarily with harm. Counts below are report volumes, not rates, and cannot be compared between drugs. The FDA itself says not to use this data to make medical decisions — we show it because you deserve to see what is in the public record, with its limits stated plainly.
- 134,360
- reports mentioning zolpidem, all time
- 92,984
- filed as serious (a report-level flag covering every drug and outcome in the report)
Most-reported reactions
- Drug ineffective8,736
- Nausea8,545
- Fatigue8,298
- Pain6,491
- Insomnia6,338
- Headache6,332
- Diarrhoea5,966
- Fall5,637
- Anxiety5,526
- Dizziness5,296
“Drug ineffective” ranking this high is worth noticing: a report of not being helped counts as an adverse event too, and people file them in large numbers.
Source: FDA Adverse Event Reporting System (FAERS), via openFDA, data through 2026-07-30.
Known interactions, from the label
The FDA label’s interactions section, verbatim. A pharmacist checking your actual medication list beats any published list — including this one.
Read the label’s interactions section
7 DRUG INTERACTIONS CNS depressants, including alcohol: Possible adverse additive CNS-depressant effects ( 5.2 , 7.1 ) Opioids: Concomitant use may increase risk of respiratory depression ( 5.7 , 7.1 ) Imipramine: Decreased alertness observed ( 7.1 ) Chlorpromazine: Impaired alertness and psychomotor performance observed ( 7.1 ) CYP3A4 inducers (rifampin or St. John's Wort): Combination use may decrease effect ( 7.2 ) Ketoconazole: Combination use may increase effect ( 7.2 )
7.1 CNS-Active Drugs CNS Depressants Coadministration of zolpidem with other CNS depressants increases the risk of CNS depression. Concomitant use of zolpidem with these drugs may increase drowsiness and psychomotor impairment, including impaired driving ability [see Warnings and Precautions (5.1 , 5.2) ] . Zolpidem tartrate was evaluated in healthy volunteers in single-dose interaction studies for several CNS drugs. Alcohol An additive adverse effect on psychomotor performance between alcohol and oral zolpidem was demonstrated [see Warnings and Precautions (5.1 , 5.2) ] . Opioids The concomitant use of zolpidem tartrate extended-release tablets with opioids may increase the risk of respiratory depression. Limit dosage and duration of concomitant use of zolpidem tartrate extended-release tablets and opioids [see Dosage and Administration (2.3) , Warnings and Precautions (5.7) ] . Imipramine, Chlorpromazine Imipramine in combination with zolpidem produced no pharmacokinetic interaction other than a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness. Similarly, chlorpromazine in combination with zolpidem produced no pharmacokinetic interaction, but there was an additive effect of decreased alertness and psychomotor performance [see Clinical Pharmacology (12.3) ] . Sertraline Concomitant administration of zolpidem and sertraline increases exposure to zolpidem [see Clinical Pharmacology (12.3) ] . Fluoxetine After multiple doses of zolpidem tartrate and fluoxetine an increase in the zolpidem half-life (17%) was observed. There was no evidence of an additive effect in psychomotor performance [see Clinical Pharmacology (12.3) ] . Haloperidol A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem. The lack of a drug interaction following single-dose administration does not predict the absence of an effect following chronic administration [see Clinical Pharmacology (12.3) ] .
7.2 Drugs that Affect Drug Metabolism via Cytochrome P450 Some compounds known to induce or inhibit CYP3A may affect exposure to zolpidem. The effect of drugs that induce or inhibit other P450 enzymes on the exposure to zolpidem is not known. CYP3A4 Inducers Rifampin Rifampin, a CYP3A4 inducer, significantly reduced the exposure to and the pharmacodynamic effects of zolpidem. Use of Rifampin in combination with zolpidem may decrease the efficacy of zolpidem and is not recommended [see Clinical Pharmacology (12.3) ] . St. John's Wort Use of St. John's Wort, a CYP3A4 inducer, in combination with zolpidem may decrease blood levels of zolpidem and is not recommended. CYP3A4 Inhibitors Ketoconazole Ketoconazole, a potent CYP3A4 inhibitor, increased the exposure to and pharmacodynamic effects of zolpidem. Consideration should be given to using a lower dose of zolpidem when a potent CYP3A4 inhibitor and zolpidem are given together [see Clinical Pharmacology (12.3) ] .
FDA label for zolpidem, effective August 26, 2026 — DailyMed.
Who pays for zolpidem
Two claims datasets and one survey, covering different populations with different instruments — they cannot be reconciled by arithmetic, and where their sum crowds the all-payer estimate, that is a finding about the estimates rather than a percentage.
- Medicare Part D
- Read the under-65 group correctly before the numbers: Medicare before 65 means the disabled and dual-eligible population — among the sickest, highest-need people in the program — and reading their utilization as typical adult use would be a category error. The beneficiary total sums brand-level rows, so treat it as an upper bound on distinct people. 1,562,877 beneficiaries filled 7,937,736 claims in 2024 — 1,335,962 aged 65 and over, and 226,915 under 65.
- Medicaid
- At least 1,613,371 prescriptions in 2024 — a floor, because 56 of 422 national data rows are suppressed for privacy and contribute zero. Medicaid covers more children than any insurer in the country and publishes no age split — how much of this number is pediatric use is not knowable from public data.
- All payers (survey estimate)
- The MEPS-based estimate above puts the whole country at 12,744,221 prescriptions and 2,420,367 people in 2024. Subtracting the public programs from it would produce a number for everyone else — and we do not print that number, because subtracting a survey from claims counts manufactures precision that does not exist.
- The population nobody counts
- The commercially insured working-age adult — statistically, the likeliest person to be reading this page — is the one population with no public per-drug count anywhere. Private claims data exists and is sold, but nothing a patient can check is published. For children the record is thinner still: no public source counts pediatric use of zolpidem specifically; the closest the public record comes is condition-level treatment rates for children, which we have traced for one condition in how childhood ADHD got counted.
Sources: Medicare Part D Prescribers — by Geography and Drug, data.cms.gov, National rows, data year 2024 (published with ~17-month lag). Medicaid State Drug Utilization Data 2024, data.medicaid.gov, national aggregate rows. Retrieved 2026-09-01.
The approval, step by step
Step 1
What the approval was actually based on
Which studies did the FDA rely on, how long did they run, and who was in them?
Adult outpatients with chronic insomnia (n=75) were evaluated in a double-blind, parallel group, 5-week trial comparing two doses of zolpidem tartrate and placebo. On objective (polysomnographic) measures of sleep latency and sleep efficiency, zolpidem 10 mg was superior to placebo on sleep latency for the first 4 weeks and on sleep efficiency for weeks 2 and 4. Zolpidem was comparable to placebo on number of awakenings at both doses studied.
FDA-approved labelling, 14 CLINICAL STUDIES 14.2 Chronic Insomnia — read the label on DailyMed
Our reading
Read the last sentence twice, because it is the one nobody quotes. Across five weeks in seventy-five people, zolpidem got them to sleep faster than placebo did — and did not reduce how often they woke up. A second trial in 141 outpatients found the benefit on subjective total sleep time, awakenings and sleep quality held for the first treatment week only. This is a drug approved for short-term use on evidence that thins out inside the first month, and the indication says so in as many words.
Step 2
The approval
When was it approved, under what application, and by whose review?
- Approved
- December 16, 1992
- Application
- NDA019908
- Review
- STANDARD
- Original sponsor
- Sanofi (now Cosette)
- Holds it now
- Cosette Pharmaceuticals
- Label submissions since
- 32
Source: openFDA Drugs@FDA, original application ORIG-1
Step 3
What was added after it was on the market
Which warnings arrived only after millions of people were already taking it?
FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower…
21 years after approval
In January 2013 the FDA halved the recommended starting dose of zolpidem for women (10 mg to 5 mg immediate-release; 12.5 mg to 6.25 mg extended-release) because next-morning blood levels can remain high enough to impair driving and alertness.
Worth asking
I'm taking 10 mg of zolpidem — given the FDA's lower recommended starting dose for women and slower metabolizers, should I be on 5 mg instead?
Z-drugs carry a boxed warning for things people do while not fully awake
27 years after approval
In April 2019 the FDA added a boxed warning to zolpidem, eszopiclone and zaleplon — the medications sold as Ambien, Lunesta and Sonata. The reason was complex sleep behaviours: sleepwalking, sleep-driving, and doing other things while not fully awake, which have caused serious injuries and deaths. These events are rare, and they have happened to people at normal doses on their first night.
The FDA also made it a contraindication. If you have ever had one of these episodes on any of these three drugs, none of them should be prescribed to you again.
Worth asking
Have I ever done anything while asleep that I could not remember, is there a non-drug option we have not tried for my sleep, and what is the plan for coming off this given how quickly tolerance builds.
FDA adds Boxed Warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia…
27 years after approval
In April 2019 the FDA added its most serious (boxed) warning to zolpidem and other z-drugs after reports of sleepwalking, sleep-driving and other complex sleep behaviors causing serious injuries and deaths, and made the drugs contraindicated for anyone who has ever had such an episode on them.
Worth asking
If I ever sleepwalk, drive, or do anything I don't remember after taking zolpidem, should I stop it immediately and call you before the next dose?
Step 4
What independent research has found since
What has been learned by people who were not selling it?
Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the…
20 years after approval
Across 13 placebo-controlled trials submitted to the FDA (4,378 people), z-drugs including zolpidem shortened lab-measured time to fall asleep by about 22 minutes versus placebo — a real but modest benefit, with a large share of the overall improvement also occurring on placebo.
Worth asking
The average benefit of zolpidem over placebo is about 20 minutes of faster sleep onset — how will we judge whether it's doing enough for me to be worth the risks?
Withdrawal from these medications can take months, and NICE says so
30 years after approval
NICE guideline NG215 covers safe prescribing and managed withdrawal for five groups of medication: opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants. It is the closest thing there is to an official answer on how coming off actually goes.
It states that withdrawal can be difficult and may take several months or more, that symptoms vary widely in type and severity, that they affect both physical and mental health, and that they can be delayed in onset and can persist. Two recommendations are worth quoting to a prescriber. Do not stop a medicine abruptly except in exceptional medical circumstances. And taper using a slow, stepwise reduction proportionate to the current dose, so the decrements get smaller as the dose gets lower — not a fixed cut each time.
That last detail is the one most commonly missed. Gabapentinoids are the exception in the guideline and are reduced by a fixed amount at each step.
Worth asking
Can we write the taper down, what size are the steps near the end, and how long do I hold at each step before the next reduction.
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in…
30 years after approval
In a network meta-analysis of 154 double-blind randomized trials (44,089 people), zolpidem and similar drugs improved sleep in the short term, but eszopiclone and lemborexant showed the most favorable balance of benefit and tolerability for longer-term treatment, and long-term data for zolpidem were limited.
Worth asking
If I still need help sleeping after a few weeks on zolpidem, what's the plan — stop, switch to a drug with better long-term evidence, or add non-drug treatment like CBT-I?
Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis
26 years after approval
Pooling 14 observational studies covering 830,877 older adults, z-drug use was associated with 1.63 times the odds of fractures, and zolpidem specifically with about twice the odds of injury (OR 2.05, 160,502 people in that analysis).
Worth asking
I'm an older adult — given the roughly doubled injury odds on zolpidem, is there a safer way for me to handle insomnia, or a reason it's still the right choice?
Step 5
What still is not known
Which questions you might reasonably have has nobody answered yet?
- The approved indication is short-term use. If you have been taking it nightly for years, you are outside both the evidence and the label.
- Sleep latency improved and number of awakenings did not. Which of those is the problem you are actually trying to solve?
- The boxed warning for complex sleep behaviours — driving and eating while not fully awake — arrived in 2019, twenty-seven years after approval.
- What happens to sleep architecture and to rebound insomnia on stopping after long-term use?
Deciding about zolpidem?
- 12 questions to ask before starting a psychiatric medication — each with the study behind it
- Already on it? The 10-question annual review — including the honest case for staying
- How long every drug here was tested before approval — one chart, all medications
Open zolpidem (Ambien) in Resolv
The app has the full approval journey, the resources behind it, and people working through the same questions.
